Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival

Figures & data

Table 1 Patient Demographics in Real-World Studies

Real-World Studies	Location	Median Age	Male	Female	ECOG 0	ECOG 1	ECOG 2	ECOG 3
Munhoz et al 2020^Citation12	Latin America	72	61	39	30	46	15	2
Grignani et al 2021^Citation9	Italy	71	78	22	51	30	4	1
Ascierto et al 2021^Citation11	Europe & Asia	72	68	32	34	36	5	2
Walker et al 2020^Citation23	Global*	73	67	33	39	52	7	2
Averbach et al 2023^Citation13	Israel	75	55	45	42	19	13	5
Bhatia et al 2022^Citation22	USA	67	58	42	0	31	42	26
Cowey et al 2021^Citation3	USA	78	86	14	7	50	11	Unknown
Levy et al 2020^Citation21	Netherlands	73	63	37	32	59	9	Unknown

Notes: *38 countries. All data are in percentages.

Abbreviation: ECOG, Eastern Cooperative Oncology Group performance score.

Table 2 Patient Response Seen in Real-World Studies

Real-World Studies	ORR	DCR	CR	PR	SD	PD
Munhoz et al 2020^Citation12	57.9	68.4	15.8	42.1	10.5	31.6
Grignani et al 2021^Citation9	29.1	60	10.9	18.2	30.9	40
Ascierto et al 2021^Citation11	48	72.7	25.4	22.7	24.7	27.3
Walker et al 2020^Citation23	46.7	71.2	22.9	23.8	24.6	28.8
Averbach et al 2023^Citation13	59	70	37	22	11	2
Bhatia et al 2022^Citation22	72.1	77.9	37.2	34.9	5.8	22
Cowey et al 2021^Citation3	39.2	46.3	32.1	7.1	7.1	7.1
Levy et al 2020^Citation21	58	63	24	33	6	28

Abbreviations: ORR, Objective Response Rate (CR+PR); DCR, Disease Control Rate (CR+PR+SD); CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive Disease.

Table 3 Adverse Events Recorded in Real-World Studies

Adverse Event	% Occurrence
Infusion-related reaction	1.8–3.2
Dyspnea	0.9–20
Fatigue	0.3–9
Thyroiditis	0.6–3
Abdominal Pain	0.3–18
Hepatitis	0.3–5

Munhoz RR, Cayol F, Corrales L, et al. Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts’ recommendations. Cancer Immunol Immunother. 2021;70(4):1031–1036. doi:10.1007/s00262-020-02756-9

 PubMed Web of Science ®Google Scholar

Grignani G, Chiarion Sileni V, Pinto C, et al. Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. J Transl Med. 2021;19(1):70. doi:10.1186/s12967-021-02730-8

 PubMed Web of Science ®Google Scholar

Ascierto PA, Orlova K, Grignani G, et al. Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer. 2021;149(11):1926–1934. doi:10.1002/ijc.33746

 PubMed Web of Science ®Google Scholar

Walker JW, Lebbé C, Grignani G, et al. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. J Immunother Cancer. 2020;8(1):e000313. doi:10.1136/jitc-2019-000313

 PubMed Web of Science ®Google Scholar

Averbuch I, Stoff R, Miodovnik M, et al. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel. Cancer Med. 2023;12(11):12065–12070. doi:10.1002/cam4.5890

 PubMed Web of Science ®Google Scholar

Bhatia S, Nghiem P, Veeranki SP, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022;10(8):e004904. doi:10.1136/jitc-2022-004904

 PubMed Web of Science ®Google Scholar

Cowey CL, Liu FX, Kim R, et al. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. Future Oncol. 2021;17(18):2339–2350. doi:10.2217/fon-2020-1250

 PubMed Web of Science ®Google Scholar

Levy S, Aarts MJB, Eskens FALM, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. J Immunother Cancer. 2020;8(2):e001076. doi:10.1136/jitc-2020-001076

 PubMed Web of Science ®Google Scholar